JF
TARA icon

Jump Financial’s Protara Therapeutics TARA Stock Holding History

Jump Financial’s Portfolio TARA Stock Details TARA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$348K Buy
+66,779
New +$395K ﹤0.01% 1416
2021
Q4 		– Sell
-14,500
Closed -$100K – 1708
2021
Q3 		$100K Buy
+14,500
New +$113K 0.01% 971

Other funds holding TARA

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
IHAM
Integral Health Asset Management New York $2.09B AUM 112.84% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

Jump Financial's TARA Position: Q1 2026 in Review

Jump Financial opened a new position in Protara Therapeutics (TARA) in Q1 2026: 66,779 shares worth $348K. The stake represents ﹤0.01% of the portfolio and ranks #1416 among its holdings. This is a return to the name: Jump Financial previously reported a position in TARA as recently as Q3 2021.

Jump Financial first reported a position in TARA in Q3 2021 and has held it in 2 quarters since. 114 funds tracked by Wall St. Rank hold TARA as of Q1 2026.

  • Jump Financial held 66,779 shares of Protara Therapeutics worth $348K as of Q1 2026.
  • Protara Therapeutics was a new Jump Financial position in Q1 2026.
  • Protara Therapeutics made up ﹤0.01% of Jump Financial's portfolio in Q1 2026, its #1416 holding.
  • Jump Financial first reported a position in Protara Therapeutics in Q3 2021 and has held it in 2 quarters since.
  • 114 funds tracked by Wall St. Rank held Protara Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.